New: NCI-funded clinical trial search
Mednet Logo
CommunityHematology

Hematology

Clinical discussions on blood disorders, coagulation, transfusion medicine, and hematologic malignancies.

Recent Discussions

Which neoadjuvant/adjuvant chemotherapy regimen would you select in a patient with resectable stage IB pancreatic head adenocarcinoma and MDS-SF3B1 on luspatercept (baseline Hgb of 8-9 g/dL)?

1
1 Answers

Mednet MemberInvited Expert
Medical Oncology · Rutgers Cancer Institute of New Jersey

Seems a bit unfair that the patient has both! First, I would consider resection upfront to ensure this key step rather than risk additional complications of chemotherapy. Perioperative or total neoadjuvant therapy is not standard for resectable disease yet (pending Alliance trial result). Second, bo...

Would you consider anti-fibrinolytics for heavy menses in patients with a history of VTE?

1 Answers

Mednet MemberInvited Expert
Hematology · University of Maryland

A recent review article provided reassuring evidence about the combined use of antifibrinolytics and estrogen in women with heavy menstrual bleeding (Meschino et al., PMID 40680937); however, it did not specifically provide data in women with a prior history of VTE. In this case, I would first ensur...

How would you counsel a woman with a strong family history of thrombosis about oral contraceptives?

2 Answers

Mednet MemberInvited Expert
Hematology · Mayo Clinic

This can be a complex question for which there are likely no specific data or guidelines upon which to base a recommendation. ASH has published guidelines on thrombophilia testing in VTE (Middeldorp et al., PMID 37195076). They specifically recommend against testing prior to COC prescription. The ra...

About Mednet

A community where doctors find answers to medicine's toughest questions.

  • Verified, credentialed physicians
  • 45,000+ members across 24 specialties
  • Free CME and MOC credit

Is your standard of care for newly diagnosed advanced classical Hodgkin now nivolumab-AVD based on SWOG 1826?

5 Answers

Mednet MemberInvited Expert
Medical Oncology · Lurie Comp Cancer Center of Northwestern Univ

I think the new standard of care for newly diagnosed patients with advanced classical Hodgkins Lymphoma is now nivolumab-AVD based on the early data from SWOG 1826. While we often wait for more mature data, the early improvement in PFS and the more favorable toxicity profile of this regimen over BvA...

What is your preferred first-line therapy for transfusion-dependent beta-thalassemia?

2
2 Answers

Mednet MemberInvited Expert
Pediatric Hematology/Oncology · Weill Cornell Medical College

Transfusions are the backbone of therapy for these individuals. Reducing transfusion burden is advantageous to minimize iron loading, space out transfusions, and improve quality of life. At present, there are 2 agents available - luspatercept and mitapivat. The clinical trial endpoints for both are ...

When consolidating DLBCL with radiotherapy, do you treat all originally involved sites, or just initially bulky and partial responder sites?

1
1 Answers

Mednet MemberInvited Expert
Radiation Oncology · University Hospital Basel

When consolidating DLBCL with radiotherapy, several parameters must be taken into consideration. a) Is radiation therapy part of the treatment plan "on top" of full systemic treatment because of a certain risk situation due to not-optimal response of disease to systemic treatment (for example, FDG-a...

Is enteric-coated aspirin acceptable to use in polycythemia vera or ET?

1
2 Answers

Mednet MemberInvited Expert
Medical Oncology · Virginia Mason Medical Center

Admittedly, this is a question I had not considered before viewing this query, as I rarely, if ever, prescribe enteric-coated aspirin. In the absence of a bleeding diathesis such as von Willebrand disease, platelet count greater than one million/mm³, or active GI bleeding, low-dose aspirin (75/81/10...

Would you consider perioperative antifibrinolytics for mild factor 7 deficiency undergoing surgery?

1 Answers

Mednet MemberInvited Expert
Hematology · UPMC

I do use antifibrinolytics in factor VII deficiency; however, it depends on the specifics of the surgery (i.e., mucosal surface surgery, sequelae of bleeding should it occur - spine vs oral), the patient's bleeding history, and the factor VII level. Here, I wonder if the original diagnosis was corre...

Can aplastic anemia present with multiple infiltrative bone lesions, such as in the spine and pelvis?

3 Answers

Mednet MemberInvited Expert
Pediatric Hematology/Oncology · St. Jude Children's Research Hospital

There are several studies showing diffuse hypointense pictures with an infiltrative-like pattern on MRI in aplastic anemia and MDS. Some aplastic anemia and refractory cytopenia of childhood show patchy pattern of hematopoiesis with some regions having increased fat fraction and some remnants of hem...

Would you use routine PET scans after two cycles of R-CHOP to guide first-line treatment de-escalation in low-risk (aaIPI = 0) DLBCL patients?

1 Answers

Mednet MemberInvited Expert
Medical Oncology · Riverside Methodist Hospitals/OhioHealth

This phase III trial suggests that in very low-risk limited-stage DLBCL (aaIPI = 0), patients who achieve a negative PET after two cycles of R-CHOP can safely receive only four total cycles instead of six, with similar 3-year PFS (92% vs 89%) and less toxicity. However, the results apply to a highly...